

# Dalcetrapib

Catalog No: tcsc0916



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

211513-37-0

**Formula:**

$C_{23}H_{35}NO_2S$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

CETP

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

JTT-705;RO4607381

**Observed Molecular Weight:**

389.59

## Product Description


Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC<sub>50</sub> of 0.2 μM that increases the plasma HDL cholesterol.

IC<sub>50</sub> value: 0.2 uM [1]

Target: CETP

in vitro: Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 μM and increased at 10 μM. Dalcetrapib statistically and significantly increases pre-β-HDL formation [1]. Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM [2]. Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner [3].

in vivo: Treatment with Dalcetrapib leads to significant increases in HDL-C levels. In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids. Dalcetrapib increases plasma HDL-[3H]cholesterol [1]. Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!